Novartis

Novartis halts cell-therapy trials after three patient deaths

Novartis has halted several experimental CAR-T cell-therapy trials after three patients died from immune-related complications. The article should explain what rap-cel is, why the trials were suspended, the known risks of CAR-T treatments and what the decision means for patients and the wider Swiss pharmaceutical sector.